Metagenomi (MGX) Competitors

Metagenomi logo
$0.57 -0.04 (-6.97%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$0.59 +0.02 (+3.33%)
As of 11/20/2026 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MGX vs. MRNA, ZURA, CBUS, ADAG, and ANIX

Should you buy Metagenomi stock or one of its competitors? Metagenomi's main competitors and comparable companies include Moderna (MRNA), Zura Bio (ZURA), Cibus (CBUS), Adagene (ADAG), and Anixa Biosciences (ANIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Metagenomi compare to Moderna?

Moderna (NASDAQ:MRNA) and Metagenomi (NASDAQ:MGX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

In the previous week, Moderna had 34 more articles in the media than Metagenomi. MarketBeat recorded 34 mentions for Moderna and 0 mentions for Metagenomi. Moderna's average media sentiment score of 0.23 beat Metagenomi's score of 0.00 indicating that Moderna is being referred to more favorably in the media.

Company Overall Sentiment
Moderna Neutral
Metagenomi Neutral

75.3% of Moderna shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 12.5% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Metagenomi has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$2.52B31.18-$2.82B-$7.10N/A
Metagenomi$7.09M3.05-$87.87M-$2.50N/A

Moderna has a net margin of -110.46% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -25.79% beat Metagenomi's return on equity.

Company Net Margins Return on Equity Return on Assets
Moderna-110.46% -25.79% -15.85%
Metagenomi -384.61%-75.04%-50.29%

Moderna has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

Moderna presently has a consensus target price of $120.25, indicating a potential downside of 38.07%. Metagenomi has a consensus target price of $6.00, indicating a potential upside of 950.79%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts clearly believe Metagenomi is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moderna
4 Sell rating(s)
15 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.08
Metagenomi
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Moderna beats Metagenomi on 10 of the 16 factors compared between the two stocks.

How does Metagenomi compare to Zura Bio?

Metagenomi (NASDAQ:MGX) and Zura Bio (NASDAQ:ZURA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Zura Bio has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Zura Bio's return on equity of -53.98% beat Metagenomi's return on equity.

Company Net Margins Return on Equity Return on Assets
Metagenomi-384.61% -75.04% -50.29%
Zura Bio N/A -53.98%-49.85%

Metagenomi has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Metagenomi$7.09M3.05-$87.87M-$2.50N/A
Zura BioN/AN/A-$99.35M-$1.12N/A

61.1% of Zura Bio shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by insiders. Comparatively, 12.4% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Metagenomi has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, Zura Bio has a beta of 0.03, suggesting that its share price is 97% less volatile than the broader market.

Metagenomi currently has a consensus target price of $6.00, suggesting a potential upside of 950.79%. Zura Bio has a consensus target price of $14.50, suggesting a potential upside of 1,458.30%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts clearly believe Zura Bio is more favorable than Metagenomi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Metagenomi
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Zura Bio
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

In the previous week, Zura Bio had 3 more articles in the media than Metagenomi. MarketBeat recorded 3 mentions for Zura Bio and 0 mentions for Metagenomi. Zura Bio's average media sentiment score of 0.08 beat Metagenomi's score of 0.00 indicating that Zura Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Metagenomi Neutral
Zura Bio Neutral

Summary

Zura Bio beats Metagenomi on 11 of the 16 factors compared between the two stocks.

How does Metagenomi compare to Cibus?

Metagenomi (NASDAQ:MGX) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Metagenomi has higher revenue and earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Metagenomi$7.09M3.05-$87.87M-$2.50N/A
Cibus$3.64M25.48-$127.08M-$1.50N/A

33.8% of Cibus shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by company insiders. Comparatively, 29.9% of Cibus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Cibus had 11 more articles in the media than Metagenomi. MarketBeat recorded 11 mentions for Cibus and 0 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.00 beat Cibus' score of -0.29 indicating that Metagenomi is being referred to more favorably in the media.

Company Overall Sentiment
Metagenomi Neutral
Cibus Neutral

Metagenomi has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, Cibus has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market.

Metagenomi has a net margin of -384.61% compared to Cibus' net margin of -2,131.38%. Metagenomi's return on equity of -75.04% beat Cibus' return on equity.

Company Net Margins Return on Equity Return on Assets
Metagenomi-384.61% -75.04% -50.29%
Cibus -2,131.38%-526.66%-28.12%

Metagenomi presently has a consensus target price of $6.00, suggesting a potential upside of 950.79%. Cibus has a consensus target price of $9.00, suggesting a potential upside of 643.80%. Given Metagenomi's stronger consensus rating and higher probable upside, equities analysts plainly believe Metagenomi is more favorable than Cibus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Metagenomi
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Cibus
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Metagenomi beats Cibus on 9 of the 16 factors compared between the two stocks.

How does Metagenomi compare to Adagene?

Metagenomi (NASDAQ:MGX) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Metagenomi has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Adagene has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Adagene has higher revenue and earnings than Metagenomi.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Metagenomi$7.09M3.05-$87.87M-$2.50N/A
Adagene$7.67M15.16-$17.61MN/AN/A

In the previous week, Adagene had 6 more articles in the media than Metagenomi. MarketBeat recorded 6 mentions for Adagene and 0 mentions for Metagenomi. Adagene's average media sentiment score of 0.43 beat Metagenomi's score of 0.00 indicating that Adagene is being referred to more favorably in the news media.

Company Overall Sentiment
Metagenomi Neutral
Adagene Neutral

Metagenomi presently has a consensus price target of $6.00, indicating a potential upside of 950.79%. Adagene has a consensus price target of $8.25, indicating a potential upside of 368.75%. Given Metagenomi's higher probable upside, analysts plainly believe Metagenomi is more favorable than Adagene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Metagenomi
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Adagene
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Adagene has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Adagene's return on equity of 0.00% beat Metagenomi's return on equity.

Company Net Margins Return on Equity Return on Assets
Metagenomi-384.61% -75.04% -50.29%
Adagene N/A N/A N/A

9.5% of Adagene shares are held by institutional investors. 12.5% of Metagenomi shares are held by insiders. Comparatively, 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Adagene beats Metagenomi on 12 of the 14 factors compared between the two stocks.

How does Metagenomi compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Anixa Biosciences has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -75.04% beat Anixa Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Anixa BiosciencesN/A -76.59% -67.80%
Metagenomi -384.61%-75.04%-50.29%

29.1% of Anixa Biosciences shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by company insiders. Comparatively, 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Anixa Biosciences has higher earnings, but lower revenue than Metagenomi. Anixa Biosciences is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anixa BiosciencesN/AN/A-$10.93M-$0.32N/A
Metagenomi$7.09M3.05-$87.87M-$2.50N/A

In the previous week, Anixa Biosciences had 6 more articles in the media than Metagenomi. MarketBeat recorded 6 mentions for Anixa Biosciences and 0 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.00 beat Anixa Biosciences' score of -0.57 indicating that Metagenomi is being referred to more favorably in the news media.

Company Overall Sentiment
Anixa Biosciences Negative
Metagenomi Neutral

Anixa Biosciences currently has a consensus price target of $8.00, suggesting a potential upside of 227.87%. Metagenomi has a consensus price target of $6.00, suggesting a potential upside of 950.79%. Given Metagenomi's higher probable upside, analysts clearly believe Metagenomi is more favorable than Anixa Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anixa Biosciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Metagenomi
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Anixa Biosciences has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

Summary

Anixa Biosciences beats Metagenomi on 8 of the 15 factors compared between the two stocks.

Get Metagenomi News Delivered to You Automatically

Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MGX vs. The Competition

MetricMetagenomiBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$21.36M$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.62%
P/E Ratio-0.2323.0732.5628.68
Price / Sales3.0514.927.725.17
Price / CashN/A21.9220.2520.77
Price / Book0.234.124.343.51
Net Income-$87.87M-$24.08M$3.51B$394.12M
7 Day Performance-17.45%-9.85%-8.07%-8.97%
1 Month Performance-30.04%-12.77%-10.29%-11.61%
1 Year Performance-62.19%-7.99%-4.70%-11.21%

Metagenomi Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MGX
Metagenomi
2.2648 of 5 stars
$0.57
-7.0%
$6.00
+950.8%
-62.2%$21.36M$7.09MN/A107
MRNA
Moderna
1.3376 of 5 stars
$207.44
-3.6%
$120.25
-42.0%
+718.6%$84.17B$1.94BN/A4,700
ZURA
Zura Bio
3.1081 of 5 stars
$1.03
-5.1%
$14.50
+1,314.6%
-74.4%$98.73MN/AN/A40
CBUS
Cibus
1.4747 of 5 stars
$1.29
+7.5%
$9.00
+597.7%
-4.0%$98.60M$3.64MN/A118
ADAG
Adagene
3.1237 of 5 stars
$1.47
-8.1%
$8.25
+460.8%
-2.2%$97.16M$7.67MN/A128

Related Companies and Tools


This page (NASDAQ:MGX) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners